Contribute Try STAT+ Today

In an effort to speed the process of getting drugs to patients around the world, the Food and Drug Administration and its counterparts in Canada and Australia on Tuesday unveiled a new pilot program that will allow the agencies to review — and potentially greenlight — cancer therapies at the same time.

Typically, drug companies have to endure the regulatory process in each country separately and will often submit applications to the agencies at different times. Under the new effort, dubbed Project Orbis, companies can file their applications to FDA, Health Canada, and the Australian Therapeutic Goods Administration and the authorities will review them concurrently and collaboratively.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.